Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 715

1.

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.

PKC-DRS2 Group., Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE.

Ophthalmology. 2006 Dec;113(12):2221-30.

PMID:
16989901
2.

Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.

Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC; PKC-DRS and PKC-DRS2 Study Groups..

Retina. 2011 Nov;31(10):2084-94. doi: 10.1097/IAE.0b013e3182111669.

PMID:
21862954
4.

The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.

Sheetz MJ, Aiello LP, Davis MD, Danis R, Bek T, Cunha-Vaz J, Shahri N, Berg PH; MBDL and MBCU Study Groups..

Invest Ophthalmol Vis Sci. 2013 Mar 11;54(3):1750-7. doi: 10.1167/iovs.12-11055.

PMID:
23404115
5.

Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).

Sheetz MJ, Aiello LP, Shahri N, Davis MD, Kles KA, Danis RP; Mbdv Study Group..

Retina. 2011 Jun;31(6):1053-9. doi: 10.1097/IAE.0b013e3181fe545f.

PMID:
21386766
6.

Ruboxistaurin: LY 333531.

[No authors listed]

Drugs R D. 2007;8(3):193-9. Review.

PMID:
17472415
7.

Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.

Strøm C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M.

Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3855-8.

PMID:
16186374
8.

Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.

Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignati L; PKC-DRS2 Study Group..

Invest Ophthalmol Vis Sci. 2009 Jan;50(1):1-4. doi: 10.1167/iovs.08-2473.

PMID:
18708615
9.
10.

Diabetic macular oedema and visual loss: relationship to location, severity and duration.

Gardner TW, Larsen M, Girach A, Zhi X; Protein Kinase C Diabetic Retinopathy Study (PKC-DRS2) Study Group..

Acta Ophthalmol. 2009 Nov;87(7):709-13. doi: 10.1111/j.1755-3768.2009.01545.x.

11.

Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy.

Girach A, Aiello LP, Milton RC, Davis MD, Danis RP, Zhi X, Sheetz MJ, Vignati L; PKC-DRS2 Study Group..

Eye (Lond). 2009 Jan;23(1):209-14. doi: 10.1038/eye.2008.324.

PMID:
18989348
12.

Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.

Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ 3rd; MBBQ Study Group..

Clin Ther. 2005 Aug;27(8):1164-80.

PMID:
16199243
13.

Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.

Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M.

Ophthalmology. 2006 Sep;113(9):1533-8.

PMID:
16828501
14.

Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.

Sahu AK, Majji AB.

Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6890; author reply 6890-1. doi: 10.1167/iovs.09-4106. No abstract available.

PMID:
21123772
15.
16.
17.
18.

Rubosixtaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review.

Gálvez MI.

Curr Diabetes Rev. 2009 Feb;5(1):14-7. Review.

PMID:
19199893
19.

[Triamcinolone in the treatment of the diabetic macular edema--one-year results].

Dusová J, Studnicka J, Rencová E, Korda V, Hejcmanová D.

Cesk Slov Oftalmol. 2008 Jul;64(4):149-52. Czech.

PMID:
18780654
20.
Items per page

Supplemental Content

Support Center